Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703460 | 0.96 | CNR2 (0.50) | CNR1CNR2MDM2ACACBSYK | |
| SCHEMBL3811888 | 0.85 | CNR1 (0.67) | CNR1CNR2XDH | |
| SCHEMBL3818740 | 0.85 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL3818299 | 0.85 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL3818296 | 0.85 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL2702331 | 0.83 | CNR2 (0.53) | CNR1CNR2ACACBKDM1A | |
| SCHEMBL3818568 | 0.83 | PTGS2 (0.41) | GPBAR1MAP4K4PTGS2 | |
| SCHEMBL2703647 | 0.83 | CNR1 (0.49) | CNR1CNR2KDM1AMAOB | |
| SCHEMBL2116976 | 0.81 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL2703719 | 0.79 | KDM4E (0.41) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629346-B2 | Pyrazinecarboxamide derivatives as CB1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-2035394-B1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-2035394-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007147746-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-20 | — | — | US | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885MDM2 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.